Low cost, rapid whole-genome sequencing
Non-Diagnostic Sequencing for Surveillance Use
Non-Diagnostic Sequencing for Surveillance Use
In addition to diagnostic COVID-19 PCR testing, PRL performs non-diagnostic, whole genome sequencing to detect and track SARS-CoV-2 variants in real time and inform both public and private health responses.
First in NY to Discover Beta and Omicron Variants
First in NY to Discover Beta and Omicron Variants
PRL’s large-scale genome sequencing workflow can identify new and potentially dangerous mutations. We were the first to discover the Beta and Omicron variants in New York State in 2021.
Public Health Data
Public Health Data
PRL’s rapid sequencing workflow has had a profound impact on epidemiologic surveillance capabilities to inform local and national public health responses. We have uploaded about 50,000 sequences to GISAID, the global access genomic data database, as of March 2022.
Sequencing Capacity
Sequencing Capacity
While PRL provides 80 percent of the sequencing capacity in New York and 2 percent of the world’s capacity, we have not reached our maximum sequencing potential and are able to take on more samples.
SARS-CoV-2 Variant Tracker
Variant prevalence over time from PRL samples
Why utilize our sequencing service?
Mitigate the Spread
Mitigate the Spread
Our non-diagnostic advanced sequencing workflow can identify circulating variants at a surveillance-level, providing critical public health information in shaping mitigation and response.
Seamless Integration
Seamless Integration
PRL has integrated a large-scale, COVID testing pipeline for direct sequencing of positive samples for variant detection.
Low Cost Burden
Low Cost Burden
Our whole-genome sequencing service is about ⅓ the cost compared to market leaders.
Quick Turnaround Time
Quick Turnaround Time
On average, sequencing results are delivered within 3-7 days.
Partner with us today
FAQs
PRL offers non-diagnostic, whole-genome sequencing of SARS-CoV-2 viral RNA. Results are to be used for research, investigational, or surveillance use only, and are not to be used to provide individual diagnosis.
Customers can either sequence a percentage of the samples sent in for PRL's SCV2 PCR workflow (biosurveillance), or specify particular samples to be sequenced (STAT).
PRL employs Illumina’s amplicon-based whole genome sequencing workflow.
The PRL whole-genome sequencing report is completed using reference-based alignment against the genome of the first ancestral SARS-CoV-2 variant. Pangolin lineages are reported.
Submit a quote request for pricing. Contact our team.
STAT sequencing starts at $160 per sample.
PRL will provide whole-genome sequencing result reports for STAT samples within 72 hours of STAT sample accessioning, not including weekends. STAT samples received by PRL prior to 10 a.m. on business days will be accessioned the day of receipt. STAT samples received after 10 a.m. or on non-business days will be accessioned on the following business day.
Samples accepted are nasopharyngeal and anterior nares swabs in viral transport media or DNA/RNA shield. Saliva samples in DNA/RNA shield are accepted. We also accept extracted RNA.
A minimum of 200 µL sample volume is required.
If feasible, STAT swab samples should be sent to PRL as soon as possible. STAT swab samples can be stored in 4°C for up to 3 days. For long-term storage, the sample should be stored in -80°C. Inform PRL whether the sample has already been heat-inactivated. All samples should be shipped on dry ice.
Sequencing data provided by PRL is for research, investigational, or surveillance use only, and is not to be reported to patients for diagnostic purposes. PRL’s sequencing service has not been reviewed by the FDA/federal regulators or New York State regulators. Sequencing services may be conducted in a facility that is not certified under the Clinical Laboratory Improvement Amendments ("CLIA").
Currently, sequencing is performed in PRL’s research and development laboratory in Long Island City, NY, which can accept samples from all 50 states.